CALIX, INC
For the period ended Mar 28, 2026. Filed Apr 22, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 28, 2026 · Filed Apr 22, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 28, 2026, no director or officer of us (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted, terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as follows:
On February 17, 2026, Cory Sindelar, Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 256,000 shares of Common Stock, at specific market prices, commencing on July 1, 2026, and continuing until all such options are exercised and the underlying shares are sold, or May 31, 2027, whichever comes first.
On February 17, 2026, Shane Eleniak, Chief Product Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Eleniak 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Eleniak 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 364,000 shares of Common Stock, at specific market prices, commencing on May 19, 2026, and continuing until all such options are exercised and the underlying shares are sold, or October 30, 2026, whichever comes first.
On February 19, 2026, Michael Weening, Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 397,100 shares of Common Stock, at specific market prices, commencing on May 21, 2026, and continuing until all such options are exercised and the underlying shares are sold, or February 19, 2027, whichever comes first.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.